Journal of Clinical Oncology, Vol 6, 89-97, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses

A Goldhirsch, RD Gelber and M Castiglione
Ludwig Institute for Cancer Research, Bern, Switzerland.

Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated with adjuvant chemotherapy (CMF) with or without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials. Three hundred fifty- two (43%) had recurrent disease at a median follow-up time of 6 years. The 2-year survival percentages from time of first relapse were 16% for patients with initial metastases in visceral or multiple sites (including bone and soft tissue), 41% for those with regional metastases or skeletal relapse alone and 70% for patients with isolated local recurrence or contralateral breast cancer. The features that most influenced prognosis within the categories defined by site of first relapse were disease-free interval (less than 24 months v greater than or equal to 24 months), and estrogen receptor content in the primary tumor. These features had clinical importance (identifying patients with at least a 50% 2-year survival percentage) only in those patients with local, contralateral breast, regional, or bony disease alone. The treatment of individual patients after relapse must be directed toward optimized palliation. The results of this study are important for defining groups of patients who relapse after CMF for whom the subsequent therapeutic approach might be differentiated (eg, experimental treatments for dire prognosis, accent on minimal side effect treatment for intermediate prognosis, and investigation of adjuvant systemic therapy for isolated local recurrence).
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. D. Timmerman, C. S. Bizekis, H. I. Pass, Y. Fong, D. E. Dupuy, L. A. Dawson, and D. Lu Local Surgical, Ablative, and Radiation Treatment of Metastases CA Cancer J Clin, May 1, 2009; 59(3): 145 - 170. [Abstract] [Full Text] [PDF]

				I. F. Faneyte, J. L. Peterse, H. van Tinteren, C. Pronk, E. G. E. de Vries, S. Rodenhuis, and M. J. van de Vijver Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement Clin. Cancer Res., July 1, 2004; 10(13): 4457 - 4463. [Abstract] [Full Text] [PDF]

				C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]

				A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569. [Abstract] [Full Text] [PDF]

				M. Colleoni, A. O'Neill, A. Goldhirsch, R. D. Gelber, M. Bonetti, B. Thurlimann, K. N. Price, M. Castiglione-Gertsch, A. S. Coates, J. Lindtner, et al. Identifying Breast Cancer Patients at High Risk for Bone Metastases J. Clin. Oncol., December 1, 2000; 18(23): 3925 - 3935. [Abstract] [Full Text] [PDF]

				A. Katz, E. A. Strom, T. A. Buchholz, H. D. Thames, C. D. Smith, A. Jhingran, G. Hortobagyi, A. U. Buzdar, R. Theriault, S. E. Singletary, et al. Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation J. Clin. Oncol., August 15, 2000; 18(15): 2817 - 2827. [Abstract] [Full Text] [PDF]

				A. Recht, R. Gray, N. E. Davidson, B. L. Fowble, L. J. Solin, F. J. Cummings, G. Falkson, H. C. Falkson, S. G. Taylor IV, and D. C. Tormey Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology Group J. Clin. Oncol., June 1, 1999; 17(6): 1689 - 1689. [Abstract] [Full Text] [PDF]

				R. D. Gelber, A. Goldhirsch, and F. Cavalli Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer Ann Intern Med, April 15, 1991; 114(8): 621 - 628. [Abstract] [PDF]